Published in IDrugs on May 01, 2004
Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain (2012) 2.13
Smoking, vaping, eating: Is legalization impacting the way people use cannabis? Int J Drug Policy (2016) 0.99
Drug vaping applied to cannabis: Is "Cannavaping" a therapeutic alternative to marijuana? Sci Rep (2016) 0.95
Medical marijuana and driving: a review. J Med Toxicol (2014) 0.80
Dosing medical marijuana: rational guidelines on trial in Washington State. MedGenMed (2007) 0.79
Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis. Neurol Clin (2015) 0.77
An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease. J Pain (2016) 0.76
Medical cannabis - the Canadian perspective. J Pain Res (2016) 0.75
Medical marijuana for the treatment of vismodegib-related muscle spasm. JAAD Case Rep (2017) 0.75
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS (2008) 5.30
Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med (2003) 4.27
HIV infection and the risk of cancers with and without a known infectious cause. AIDS (2009) 3.13
Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS (2003) 2.66
Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol (2009) 2.35
It's time for clinicians to reconsider their proscription against the use of soyfoods by breast cancer patients. Oncology (Williston Park) (2013) 2.07
HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev (2011) 2.02
The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials (2002) 1.73
Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS (2007) 1.72
Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr (2008) 1.49
Contrasts, conflicts, and change: A case in cultural oncology. J Support Oncol (2006) 1.40
AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol (2007) 1.25
Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care (2004) 1.11
Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS (2012) 1.07
A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset. Hum Mol Genet (2012) 1.06
The role of PGC-1α in the pathogenesis of neurodegenerative disorders. Curr Drug Targets (2010) 0.98
Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. BMC Infect Dis (2013) 0.98
HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons. AIDS (2011) 0.98
Dynein mutations associated with hereditary motor neuropathies impair mitochondrial morphology and function with age. Neurobiol Dis (2013) 0.96
Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma. Clin Cancer Res (2012) 0.96
PGC-1α is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Hum Mol Genet (2013) 0.96
Prostate cancer incidence and prostate-specific antigen testing among HIV-positive and HIV-negative men. J Acquir Immune Defic Syndr (2014) 0.94
Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J Neurochem (2004) 0.94
Skeletal muscle in amyotrophic lateral sclerosis: emerging concepts and therapeutic implications. Phys Med Rehabil Clin N Am (2005) 0.92
Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study. J Acquir Immune Defic Syndr (2006) 0.91
Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization. Ann Neurol (2014) 0.90
Nadir CD4+ T cell count predicts response to subcutaneous recombinant interleukin-2. Clin Infect Dis (2003) 0.90
Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol (2002) 0.89
Do antiretrovirals reduce the risk of non-AIDS-defining malignancies? Curr Opin HIV AIDS (2009) 0.88
Current pharmacological management of amyotrophic [corrected] lateral sclerosis and a role for rational polypharmacy. Expert Opin Pharmacother (2004) 0.87
Hematopoietic cell transplant and use of massage for improved symptom management: results from a pilot randomized control trial. Evid Based Complement Alternat Med (2012) 0.86
The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS (2002) 0.85
Development, implementation, and evaluation of a movie-based curriculum to teach psychopathology. Teach Learn Med (2014) 0.84
Can lesions to the motor cortex induce amyotrophic lateral sclerosis? J Neurol (2013) 0.84
The efficacy of distant healing for human immunodeficiency virus--results of a randomized trial. Altern Ther Health Med (2006) 0.83
Colon cancer survival with herbal medicine and vitamins combined with standard therapy in a whole-systems approach: ten-year follow-up data analyzed with marginal structural models and propensity score methods. Integr Cancer Ther (2011) 0.83
Inflammatory mediators and growth factors in the spinal cord of G93A SOD1 rats. Neuroreport (2004) 0.82
The BraveNet prospective observational study on integrative medicine treatment approaches for pain. BMC Complement Altern Med (2013) 0.82
Integrating dietary supplements into cancer care. Integr Cancer Ther (2013) 0.81
Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study. Am J Hosp Palliat Care (2005) 0.81
Massage for children undergoing hematopoietic cell transplantation: a qualitative report. Evid Based Complement Alternat Med (2012) 0.80
Patients seek integrative medicine for preventive approach to optimize health. Explore (NY) (2012) 0.80
Dosing medical marijuana: rational guidelines on trial in Washington State. MedGenMed (2007) 0.79
Drug therapy for amyotrophic lateral sclerosis: Where are we now? IDrugs (2003) 0.79
Cannabis: old medicine with new promise for neurological disorders. Curr Opin Investig Drugs (2002) 0.78
Non-AIDS-Defining Malignancies in the HIV-Infected Population. Curr Infect Dis Rep (2014) 0.78
Neuropathology of partial PGC-1α deficiency recapitulates features of mitochondrial encephalopathies but not of neurodegenerative diseases. Neurodegener Dis (2013) 0.77
Cannabis in palliative medicine: improving care and reducing opioid-related morbidity. Am J Hosp Palliat Care (2011) 0.77
Assessing the Association between Leptin and Bone Mineral Density in HIV-Infected Men. AIDS Res Treat (2012) 0.77
Progranulin bridges energy homeostasis and fronto-temporal dementia. Cell Metab (2012) 0.76
Can clinicians now assure their breast cancer patients that soyfoods are safe? Womens Health (Lond Engl) (2010) 0.76
Stromal immune infiltration in HIV-related diffuse large B-cell lymphoma is associated with HIV disease history and patient survival. AIDS (2015) 0.75
New insights into the role of HIV infection on cancer risk. Lancet Oncol (2009) 0.75
Full-length PGC-1α salvages the phenotype of a mouse model of human neuropathy through mitochondrial proliferation. Hum Mol Genet (2013) 0.75
What's the alternative? N Engl J Med (2012) 0.75
Targeting toxic proteins for turnover. Nat Med (2005) 0.75
Not soy simple. J Soc Integr Oncol (2010) 0.75
Using Medical Cannabis in an Oncology Practice. Oncology (Williston Park) (2016) 0.75
Nausea at the end of adjuvant cancer treatment in relation to exercise during treatment in patients with breast cancer. Oncol Nurs Forum (2008) 0.75
Electrodiagnostic evaluation of hereditary motor and sensory neuropathies. Phys Med Rehabil Clin N Am (2003) 0.75